BPC-157 dosing: routes, doses, stack timing

Verified May 10, 2026: BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of human gastric juice protein. It has not been approved by the FDA for any indication. Animal studies and user-reported protocols are the only sources of dosing information, and the ranges below reflect what shows up consistently across both.

Typical dose ranges

Across the published animal literature and the most-cited self-experiment protocols, three dose tiers recur:

• Low: 100-200 mcg/day — reported for general connective-tissue support, gut symptom management, and sleep adjacency.
• Standard: 200-500 mcg/day — the most-reported range for tendon, ligament, and muscle injury recovery protocols.
• High: 500-1000 mcg/day — reported in acute injury protocols for short cycles. Diminishing returns above 750 mcg show up in animal data.

Once-daily and split-dose (twice daily) protocols both appear. Animal half-life data suggests a once-daily protocol is sufficient for most tissue effects.

Routes

Three routes show up in the literature and protocols:

• Subcutaneous (subQ): the most common route in user protocols. Injection near the site of injury is widely reported as a positioning convention; systemic delivery is what the animal data supports.
• Intramuscular (IM): reported less commonly. No clear evidence IM is superior to subQ for most indications.
• Oral: BPC-157 is reported to survive gastric transit better than most peptides because it originated in gastric juice. Some protocols use oral delivery for GI-specific indications. Bioavailability for systemic effects is debated.

Reconstitution and dose volume

BPC-157 ships as a lyophilized powder, typically in 5 mg or 10 mg vials. Reconstitution math is identical to compounded GLP-1s:

A 5 mg (5,000 mcg) vial in 2 mL gives 2,500 mcg/mL. A 250 mcg dose works out to 0.10 mL, or 10 units on a U-100 syringe. Use Titrate's reconstitution calculator to skip the math entirely.

Cycle length

User-reported protocols cluster around two patterns:

• Short cycles (4-6 weeks) for acute injury
• Long cycles (8-12 weeks) for chronic tendinopathy or post-surgical recovery, often paired with a 4-week off period

Continuous dosing past 12 weeks is reported but not well-studied. Most protocols cycle off and reassess.

Common stacks

Two pairings dominate:

• BPC-157 + TB-500 (Thymosin Beta-4 fragment): paired for soft-tissue injury, with TB-500 dosed less frequently (often 2-4 mg per week) due to a longer reported half-life.
• BPC-157 + Ipamorelin/CJC-1295: paired in recovery-and-sleep protocols. Timing matters — most protocols dose BPC-157 in the morning and the GH secretagogues at night.

Storage

Lyophilized BPC-157 is stable at room temperature for shipping but should be stored refrigerated for long-term hold. Once reconstituted with bacteriostatic water, refrigerate and use within 30 days. Avoid freezing reconstituted peptide.

What Titrate tracks for this

The reconstitution calculator handles BPC-157 the same way it handles GLP-1s: vial mg, BAC water, target dose, syringe units. The compound library ships with BPC-157 preloaded, including its half-life for plasma-decay charting.

For users running BPC-157 alongside a GLP-1 or in a research-peptide stack, the multi-compound view overlays both curves so cycle timing and overlap windows are visible. Side-effect logs anchor to the curve.

Frequently asked questions

Is BPC-157 legal?

BPC-157 is sold legally in the US as a research chemical. It is not FDA-approved for human use. The FDA placed it on the 503A do-not-compound list in 2023, which restricts how it can be prescribed by compounding pharmacies but does not affect research-chemical sale.

How long does it take to feel BPC-157 effects?

Animal data and user reports suggest tissue effects begin within 7-14 days of consistent dosing. GI effects (acid-reflux symptoms, gut comfort) are often reported within the first week.

Should I cycle on and off BPC-157?

Most protocols cycle 8-12 weeks on, 4 weeks off. Continuous dosing past 12 weeks is reported but not well-studied. Cycling allows reassessment of whether the protocol is still needed.

Can I stack BPC-157 with a GLP-1?

Many users do, especially for GI tolerance during semaglutide or tirzepatide titration. There are no documented interactions, but no clinical data either. Track timing and side effects via Titrate's multi-compound stack view.